汉坦病毒恐慌让 3 只 Covid-Era 股票重回聚光灯下

The hantavirus outbreak on the MV Hondius lifted one mRNA leader 36% off May lows before profit-taking trimmed the rally. The brief move reactivated the pandemic-prep trade across medical stocks, putting three Covid-era stocks back on the 2026 comeback watchlist. Each setup carries a different signal. One name has already moved on to the mRNA platform strength. Another builds an inverse base as the biodefense contractor. The third offers a contrarian play loaded with bears. May 2026 is when each chart picks a side. Note: mRNA, short for messenger RNA, is the vaccine platform behind the COVID-19 shots, delivering genetic instructions to cells instead of using a live virus. Moderna (NASDAQ: MRNA) Among the Covid-era stocks rotating back into focus, Moderna stock rallied 36.08% from $43.69 on May 1 to $59.45 on May 11. Volume rose alongside price throughout the climb, confirming buying pressure rather than short covering. Want more insights like this? Sign up for Editor Harsh Notariya’s Daily Newsletter here. Three catalysts drove the move. Q1 2026 revenue grew 260% year-over-year to $389 million; the company disclosed a hantavirus vaccine collaboration with the US Army Medical Research Institute of Infectious Diseases; and Phase 3 mRNA-1010 flu data were published in the New England Journal of Medicine. Moderna’s price now sits near $54.05, consolidating in what resembles the handle of a cup-and-handle continuation pattern. The cup bottom anchors at $43.69, and the rim sits near $59.45. The handle is forming above the 20-day Exponential Moving Average (EMA), a trend indicator that weights recent price action more heavily, currently at $50.50. Cup-and-handle patterns can fail if the handle retraces deeper than half the cup, which would put the bullish thesis in question. The pattern stays valid as long as $51.17 holds. A daily close below opens the way to the 20-day EMA at $50.50 and the 50-day EMA at $49.75. A break under $43.69 invalidates the pattern entirely. A daily close above $54.91 starts the handle breakout. A move above $60.96, which aligns with the upward-sloping neckline and the 0.618 Fibonacci level, confirms the breakout and projects a measured move to $81.46, roughly 33.59% above current levels. Moderna already took its leg up. A smaller name (EBS) behind the US pandemic stockpile has not. Emergent BioSolutions (NYSE: EBS) Among the Covid-era stocks with the steepest drawdowns, Emergent stock manufactured Johnson & Johnson’s COVID-19 vaccine at its Baltimore Bayview facility under a $480 million contract. A 2021 contamination scandal that ruined 15 million doses then triggered a multi-year de-rating. The stock corrected 44.36% from $14.07 to $7.53 earlier this year. The trigger was Emergent guiding FY26 revenue to $720-760 million on March 1, below consensus. A second leg followed on April 30, when Q1 2026 revenue fell 30% year-over-year to $156.1 million, driven by weaker sales of anthrax and smallpox medical countermeasures. That second dip created the head of an inverse head-and-shoulders pattern. The left shoulder formed near $7.82 in late March. The head dipped to $7.53 in early May. The right shoulder is now forming at $8.33 with visibly weaker selling pressure. That weakening pressure suggests the de-rating may have exhausted. Inverse head-and-shoulders patterns fail when the right shoulder dips below the head, which would put the floor in question. A daily close below $8.33 weakens the structure. A break under $7.53 invalidates the pattern entirely. A daily close above $10.02, which aligns with the neckline and the 0.786 Fibonacci level, confirms the breakout. The measured move projects 25.76% upside toward $12.65, with the prior high at $14.07 capping the extended target. Emergent’s pattern is set. The final chart shows the contrarian mRNA name loaded with bear positioning. BioNTech (NASDAQ: BNTX) Among the Covid-era stocks with the most direct mRNA platform pedigree, BioNTech co-developed COMIRNATY with Pfizer. The partners delivered 2.6 billion doses across 165 countries in 2021. Peak revenue hit €18.98 billion that year. Since March 10, BNTX has carved a standard head-and-shoulders pattern. The left shoulder formed in mid-March near $100. The head peaked at $113.55 in early April. The right shoulder is now forming at $93.63, just above a neckline at $92.39. The contrarian read sits in the Chaikin Money Flow (CMF), a proxy for institutional flows. Since February 20, the price has trended lower, while the CMF has trended higher off its low. That bullish divergence often precedes false breakdowns. Positioning data backs the contrarian setup. BioNTech reported a Q1 2026 net loss of $2.28 per share on May 5. The put-call ratio, which compares bearish put options to bullish call options, now sits at 2.23 by volume and 1.15 by open interest. That extreme bear skew creates short-squeeze fuel if $92.39 holds. A daily close below $92.39 confirms a breakdown toward $86.64. The next supports sit at $79.31 and $72.36, the full measured move target. A daily close above $100.47 starts the contrarian play by invalidating the right shoulder. A move above $113.55 negates the entire bearish pattern. Head-and-shoulders patterns fail when the right shoulder breaks the head, invalidating the bearish setup completely. For now, $92.39 separates this contrarian Covid-era stock’s rebound from a $72.36 measured move downside.